Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
COVID-19
COVID-19 Update
Evaluate Vantage COVID-19 Report
COVID-19 Stories from Evaluate Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
EvaluatePharma
Evaluate Omnium
Japan Drug Forecasts
European Drug Forecasts
Epi Analyzer
Evaluate Custom Solutions
Evaluate Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Evaluate Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Medivir
September 27, 2017
Therapy focus – mostly pain and little gain for osteoarthritis research
September 05, 2016
Odanacatib’s 15 minutes of fame
May 06, 2016
Upcoming events – Achillion combo data and Agios rare disease play
January 29, 2016
Looking for a hep C price war? Merck just started it
May 20, 2015
J&J enlivens spent hep C franchise with Achillion deal
April 09, 2015
Zero-sum hep C space awaits next-generation agents
October 23, 2014
Data in 14 has Regulus joining ranks of hep C high flyers
September 30, 2014
J&J hangs in hep C game with $1.8bn Alios takeout
August 06, 2014
Vantage point – Huge hep C costs prompt search for when and where to treat
June 11, 2014
Spotlight on Achillion as post-Sovaldi world takes shape
April 10, 2014
EASL – Merck breaks from pack with promising hep C data
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
December 10, 2020
Evaluate Vantage 2021 Preview
July 29, 2020
Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020
Editor's Picks
December 10, 2020
What the coming year might hold for biopharma
December 11, 2020
Covid-19 vaccine developers remind the world that setbacks happen
December 09, 2020
Astrazeneca’s vaccine looks increasingly like an also-ran
November 09, 2020
Pfizer and Biontech snatch first Covid vaccine victory
December 01, 2020
The promise and the perils of antigen testing